Drug resistance | Overall | Lineages | P | Compensatory mutations | P | ||
---|---|---|---|---|---|---|---|
Lineage 2 | Lineage 4 | 0 | ≥1 | ||||
Overall (n, %) | 997 (100.00) | 802 (80.44) | 195 (19.56) | - | 793 (79.54) | 204 (20.46) | - |
Sampling region | 0.454 | Â | Â | 0.131 | |||
Zhejiang | 733 (73.52) | 585 (79.81) | 148 (20.19) | Â | 592 (80.76) | 141 (19.24) | Â |
Shanghai | 264 (26.48) | 217 (82.20) | 47 (17.80) | Â | 201 (76.14) | 63 (23.86) | Â |
Susceptibility profile (n, %) | 0.375* |  |  | < 0.001* | |||
Sensitive | 726 (72.82) | 577 (79.48) | 149 (20.52) | Â | 603 (83.06) | 123 (16.94) | Â |
Non-MDR | 199 (19.96) | 164 (82.41) | 35 (17.59) | Â | 158 (79.40) | 41 (20.60) | Â |
MDR | 51 (5.12) | 45 (88.24) | 6 (11.76) | Â | 27 (52.94) | 24 (47.06) | Â |
Pre-XDR | 21 (2.11) | 16 (76.19) | 5 (23.81) | Â | 5 (23.81) | 16 (76.19) | Â |
Drug resistance (n, %) | Â | Â | Â | Â | |||
INH-resistant | 152 (15.25) | 121 (79.61) | 31 (20.39) | 0.864 | 93 (61.18) | 59 (38.82) | < 0.001 |
RFP-resistant | 89 (8.93) | 77 (86.52) | 12 (13.48) | 0.169 | 45 (50.56) | 44 (49.44) | < 0.001 |
EMB-resistant | 66 (6.62) | 54 (81.82) | 12 (18.18) | 0.896 | 31 (46.97) | 35 (53.03) | < 0.001 |
PZA-resistant | 46 (4.61) | 39 (84.78) | 7 (15.22) | 0.569 | 18 (39.13) | 28 (60.87) | < 0.001 |
SM-resistant | 123 (12.34) | 107 (86.99) | 16 (13.01) | 0.067 | 76 (61.79) | 47 (38.21) | < 0.001 |
FLQ-resistant | 61 (6.12) | 47 (77.05) | 14 (22.95) | 0.601 | 39 (63.93) | 22 (36.07) | 0.003 |
AM-resistant | 14 (1.40) | 13 (92.86) | 1 (7.14) | 0.326* | 7 (50.00) | 7 (50.00) | 0.013* |
KM-resistant | 8 (0.80) | 6 (75.00) | 2 (25.00) | 0.658* | 4 (50.00) | 4 (50.00) | 0.060* |
CM-resistant | 8 (0.80) | 7 (87.50) | 1 (12.50) | 1.000* | 6 (75.00) | 2 (25.00) | 0.670* |
ETO-resistant | 36 (3.61) | 28 (77.78) | 8 (22.22) | 0.844 | 19 (52.78) | 17 (47.22) | < 0.001 |
PAS-resistant | 10 (1.00) | 8 (80.00) | 2 (20.00) | 1.000* | 8 (80.00) | 2 (20.00) | 1.000* |